Back to Atlas
CTransientStandard research/education caution
CMP-0340
Approved in some markets; prohibited in sport
Gestrinone
Endocrine / AAS-adjacent
Endometriosis drug with androgenic steroid properties
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Synthetic steroid
- Primary mechanism
- Progestogenic/antiestrogenic/androgenic activity; A:A ratio not meaningful
- Primary market use
- Endometriosis; doping relevance
Pharmacology
- Molecular weight (Da)
- 308.42
- Oral bioavailability
- Oral; clinically active
- Half-life
- ~24 h
- Route tags
- Route-dependent / verify
- Evidence level
- Approved/historical
- Clinical status
- Approved in some markets; prohibited in sport
- Value-for-money score
- 3 / 10
Reported protocol signal
No popular protocol verified yet; keep as reference compound until protocol signal is added.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
Not primarily a muscle-building anabolic despite androgenic activity.